Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT05717998

Imaging and Blood-Based Biomarkers for the Evaluation of Early Signs of Myocardial Injury After Thoracic Radiation Therapy

A Pilot Study to Evaluate Early Signs of Myocardial Injury After Thoracic Radiotherapy Using Imaging and Blood-Based Biomarkers

Status
Active Not Recruiting
Phase
Study type
Observational
Enrollment
28 (actual)
Sponsor
Ohio State University Comprehensive Cancer Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study assesses for early signs of damage to the heart following chest radiation therapy using both imaging (cardiac magnetic resonance imaging and cardiac positron emission tomography) and changes in blood biomarkers. This study determines if any changes in the heart muscle can be detected either during the course of radiation therapy or shortly thereafter using specialized imaging techniques or blood tests. Cardiac magnetic resonance imaging may be used to help provide information about changes in the heart structure and function following radiation therapy. Positron emission tomography looks at differences in how the heart takes up radioactive sugar which is injected into the vein to assess changes in heart function following radiation therapy. This study may help identify patients at risk of heart issues following radiation therapy to the chest and ultimately help in the development of more effective and safe treatments for cancer in the future.

Detailed description

PRIMARY OBJECTIVES: I. To evaluate and quantitate early changes in myocardial fibrosis following thoracic radiation therapy (RT). II. To assess quantitative early changes in myocardial inflammation after thoracic RT. III. To determine if thoracic RT is associated with early changes in myocardial metabolism as assessed with cardiac positron emission tomography (PET). SECONDARY OBJECTIVES: I. To evaluate and quantitate early changes in subclinical myocardial dysfunction after thoracic RT. II. To determine if thoracic RT is associated with early changes in myocardial metabolism using alternative cardiac PET-derived biomarkers. III. To evaluate and quantitate early changes in blood-based biomarkers after thoracic RT. IV. To assess the incidence and severity of cardiac events following completion of thoracic RT. OUTLINE: Within 2 weeks of starting RT, patients undergo cardiac magnetic resonance (CMR) imaging, cardiac positron emission tomography (PET)/computed tomography (CT) and blood sample collection at baseline, then between fractions 12-17 of RT and at 6 months after completion of RT.

Conditions

Interventions

TypeNameDescription
PROCEDUREBiospecimen CollectionUndergo blood sample collection
PROCEDUREComputed TomographyUndergo cardiac PET/CT
PROCEDUREMagnetic Resonance Imaging of the HeartUndergo CMR
PROCEDUREPositron Emission TomographyUndergo cardiac PET/CT

Timeline

Start date
2021-04-02
Primary completion
2026-06-18
Completion
2026-06-18
First posted
2023-02-08
Last updated
2026-01-02

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05717998. Inclusion in this directory is not an endorsement.

Imaging and Blood-Based Biomarkers for the Evaluation of Early Signs of Myocardial Injury After Thoracic Radiation Thera (NCT05717998) · Clinical Trials Directory